Search
Back

Rivaroxaban

CAS 366789-02-8
Rivaroxaban

General Information

In its finished dose formulation, Rivaroxaban is an oral anti-clotting substance (anticoagulant drug) which is used in the following instances: to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement surgery; to prevent stroke and systemic embolism (in patients with atrial fibrillation); to treat DVT and PE and to reduce the risk of recurrent DVT and PE.


About the API

Technology Synthetic
Therapeutic category Coagulation Inhibitors
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Rivaroxaban

May 28, 2017
New BR DMF dated 04/2017 is available.
March 27, 2018
New Canada DMF is available.
March 27, 2018
New US DMF is available.
December 27, 2018
New EU DMF is available.
October 1, 2023
CADIFA

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.